文献速递糖尿病

二甲双胍对心血管疾病的影响:2型糖尿病患者随机试验的Meta分析

Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes.
PubMed 文献 · Diabetologia · 2017-08-02

该Meta分析纳入13项随机试验(二甲双胍组共2079例2型糖尿病患者),比较二甲双胍与无干预、安慰剂或生活方式干预对心血管结局的影响。除卒中外,全因死亡、心血管死亡、心肌梗死和外周血管疾病均倾向于二甲双胍,但均未达统计学显著,卒中无差异;作者认为二甲双胍能否降低心血管风险仍不确定。

要点

  • 全因死亡RR 0.96(95%CI 0.84,1.09)、心血管死亡RR 0.97(95%CI 0.80,1.16),均未达统计学显著。
  • 心肌梗死RR 0.89(95%CI 0.75,1.06)、外周血管疾病RR 0.81(95%CI 0.50,1.31),均未达统计学显著。
  • 卒中RR 1.04(95%CI 0.73,1.48),未达统计学显著;UKPDS对汇总估计贡献权重52.3%–70.5%。

核心结论

  • 二甲双胍能否降低2型糖尿病患者心血管疾病风险仍存在不确定性,尽管该药是推荐的一线药物。
  • 作者认为这主要归因于证据缺乏,且针对糖尿病患者的确切安慰剂对照心血管终点试验不太可能开展。

研究设计与样本

  • 电子检索MEDLINE、EMBASE和Cochrane Library,并手工筛查既往二甲双胍Meta分析的参考文献列表。
  • 纳入比较任何剂量和剂型口服二甲双胍与无干预、安慰剂或生活方式干预、报告死亡或心血管结局的成人2型糖尿病随机对照试验。
  • 共纳入10篇文章报告13项试验,二甲双胍组共2079例2型糖尿病患者,对照组人数相近;其中仅4项试验比较二甲双胍与安慰剂并收集心血管结局数据。
  • 受试者主要为白人、年龄≤65岁、超重/肥胖且血糖控制不佳。

主要发现

  • 汇总估计基于少量事件:7项研究共416例心肌梗死/缺血性心脏病事件,4项研究共111例卒中。
  • UKPDS对汇总估计贡献了大部分数据,权重从心肌梗死的52.3%到卒中的70.5%。
  • 除卒中外,所有结局均倾向于二甲双胍,研究间异质性有限,但均未达统计学显著。
  • 效应量(Mantel-Haenszel RR):全因死亡0.96(95%CI 0.84,1.09);心血管死亡0.97(95%CI 0.80,1.16);心肌梗死0.89(95%CI 0.75,1.06);卒中1.04(95%CI 0.73,1.48);外周血管疾病0.81(95%CI 0.50,1.31)。

临床怎么用

  • 作者认为,减少不确定性的替代方法包括:在长期实用性评价中使用电子健康记录、将二甲双胍纳入析因试验、发表二甲双胍试验不良事件报告中的心血管结局数据,以及在非糖尿病人群中开展二甲双胍心血管终点试验。

局限性

  • 仅4项试验比较二甲双胍与安慰剂并收集心血管结局数据。
  • 汇总估计基于少量事件:7项研究共416例心肌梗死/缺血性心脏病事件,4项研究共111例卒中。
  • UKPDS对汇总估计贡献了大部分数据,权重从心肌梗死的52.3%到卒中的70.5%。
  • 作者指出,二甲双胍能否降低心血管风险仍存在不确定性,主要归因于证据缺乏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Metformin is the most-prescribed oral medication to lower blood glucose worldwide. Yet previous systematic reviews have raised doubts about its effectiveness in reducing risk of cardiovascular disease, the most costly complication of type 2 diabetes. We aimed to systematically identify and pool randomised trials reporting cardiovascular outcomes in which the effect of metformin was 'isolated' through comparison to diet, lifestyle or placebo. METHODS: We performed an electronic literature search of MEDLINE, EMBASE and the Cochrane Library. We also manually screened the reference lists of previous meta-analyses of trials of metformin identified through a MEDLINE search. We included randomised controlled trials of adults with type 2 diabetes comparing any dose and preparation of oral metformin with no intervention, placebo or a lifestyle intervention and reporting mortality or a cardiovascular outcome. RESULTS: We included ten articles reporting 13 trials (including a total of 2079 individuals with type 2 diabetes allocated to metformin and a similar number to comparison groups) of which only four compared metformin with placebo and collected data on cardiovascular outcomes. Participants were mainly white, aged ≤65 years, overweight/obese and with poor glycaemic control. Summary estimates were based on a small number of events: 416 myocardial infarctions/ischaemic heart disease events in seven studies and 111 strokes in four studies. The UK Prospective Diabetes Study (UKPDS) contributed the majority of data to the summary estimates, with weights ranging from 52.3% for myocardial infarction to 70.5% for stroke. All outcomes, with the exception of stroke, favoured metformin, with limited heterogeneity between studies, but none achieved statistical significance. Effect sizes (Mantel-Haenszel RR) were: all-cause mortality 0.96 (95% CI 0.84, 1.09); cardiovascular death 0.97 (95% CI 0.80, 1.16); myocardial infarction 0.89 (95% CI 0.75, 1.06); stroke 1.04 (95% CI 0.73, 1.48); and peripheral vascular disease 0.81 (95% CI 0.50, 1.31). CONCLUSIONS/INTERPRETATION: There remains uncertainty about whether metformin reduces risk of cardiovascular disease among patients with type 2 diabetes, for whom it is the recommended first-line drug. Although this is mainly due to absence of evidence, it is unlikely that a definitive placebo-controlled cardiovascular endpoint trial among people with diabetes will be forthcoming. Alternative approaches to reduce the uncertainty include the use of electronic health records in long-term pragmatic evaluations, inclusion of metformin in factorial trials, publication of cardiovascular outcome data from adverse event reporting in trials of metformin and a cardiovascular endpoint trial of metformin among people without diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Griffin SJ, Leaver JK, Irving GJ, et al. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia. 2017. PMID: 28770324. doi:10.1007/s00125-017-4337-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。